Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Broquetas, Teresa
  • dc.contributor.author Garcia-Retortillo, Montserrat
  • dc.contributor.author Micó, Miquel
  • dc.contributor.author Canillas, Lidia
  • dc.contributor.author Puigvehí, Marc
  • dc.contributor.author Cañete Hidalgo, Nuria
  • dc.contributor.author Coll Estrada, Susanna
  • dc.contributor.author Viu, Ana
  • dc.contributor.author Hernández, Juan José
  • dc.contributor.author Bessa Caserras, Xavier
  • dc.contributor.author Carrión Rodríguez, José Antonio
  • dc.date.accessioned 2022-03-01T08:30:04Z
  • dc.date.available 2022-03-01T08:30:04Z
  • dc.date.issued 2020
  • dc.description.abstract Background: Hepatitis B e antigen-negative chronic hepatitis B patients under nucleos(t)ids analogues (NAs) rarely achieve hepatitis B surface antigen (HBsAg) loss. Aim: To evaluate if the addition of pegylated interferon (Peg-IFN) could decrease HBsAg and hepatitis B core-related antigen (HBcrAg) levels and increase HBsAg loss rate in patients under NAs therapy. Methods: Prospective, non-randomized, open-label trial evaluating the combination of Peg-IFN 180 µg/week plus NAs during forty-eight weeks vs NAs in monotherapy. Hepatitis B e antigen-negative non-cirrhotic chronic hepatitis B patients of a tertiary hospital, under NAs therapy for at least 2 years and with undetectable viral load, were eligible. Patients with hepatitis C virus, hepatitis D virus or human immunodeficiency virus co-infection and liver transplanted patients were excluded. HBsAg and HBcrAg levels (log10 U/mL) were measured at baseline and during ninety-six weeks. HBsAg loss rate was evaluated in both groups. Adverse events were recorded in both groups. The kinetic of HBsAg for each treatment group was evaluated from baseline to weeks 24 and 48 by the slope of the HBsAg decline (log10 IU/mL/week) using a linear regression model. Results: Sixty-five patients were enrolled, 61% receiving tenofovir and 33% entecavir. Thirty-six (55%) were included in Peg-IFN-NA group and 29 (44%) in NA group. After matching by age and treatment duration, baseline HBsAg levels were comparable between groups (3.1 vs 3.2) (P = 0.25). HBsAg levels at weeks 24, 48 and 96 declined in Peg-IFN-NA group (-0.26, -0.40 and -0.44) and remained stable in NA group (-0.10, -0.10 and -0.10) (P < 0.05). The slope of HBsAg decline in Peg-IFN-NA group (-0.02) was higher than in NA group (-0.00) (P = 0.015). HBcrAg levels did not change. Eight (22%) patients discontinued Peg-IFN due to adverse events. The HBsAg loss was achieved in 3 (8.3%) patients of the Peg-IFN-NA group and 0 (0%) of the NA group. Conclusion: The addition of Peg-IFN to NAs caused a greater and faster decrease of HBsAg levels compared to NA therapy. Side effects of Peg-IFN can limit its use in clinical practice.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Broquetas T, Garcia-Retortillo M, Micó M, Canillas L, Puigvehí M, Cañete N, et al. Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. World J Hepatol. 2020 Nov 27; 12(11): 1076-88. DOI: 10.4254/wjh.v12.i11.1076
  • dc.identifier.doi http://dx.doi.org/10.4254/wjh.v12.i11.1076
  • dc.identifier.issn 1948-5182
  • dc.identifier.uri http://hdl.handle.net/10230/52596
  • dc.language.iso eng
  • dc.publisher Baishideng Publishing Group
  • dc.rights Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/License s/by-nc/4.0/
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/License s/by-nc/4.0/
  • dc.subject.keyword Chronic hepatitis B
  • dc.subject.keyword Hepatitis B core-related antigen
  • dc.subject.keyword Hepatitis B e antigen-negative
  • dc.subject.keyword Hepatitis B surface antigen
  • dc.subject.keyword Nucleos(t)ids analogues
  • dc.subject.keyword Pegylated-interferon
  • dc.title Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)